A study by Dr. Raymond U. Osarogiagbon and colleagues found that such programs may benefit patients deemed too young or too old for lung cancer screening based on existing guidelines. Read more
As the IASLC celebrates its 50th year, the association’s journal moves to online only and the American Cancer Society recommends expanding screening eligibility. Read more
Dr. Jens Vogel-Claussen says the PLCOm2012 model, which includes family history and other factors, detected 97% of lung cancer cases compared to a 77% detection rate with NELSON criteria. Read more
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap. Read more
During ACLC 2022, Dr. Gee-Chen Chang made the case for moving beyond smoking history to identify at-risk patients and shared an alternative risk predication model that compared favorably against NLST and NELSON. Read more
Prof. Denis Horgan, executive director for the European Alliance for Personalised Medicine, writes that while the intentions behind the EU’s new cancer screening recommendations are laudable, they lack a roadmap for turning ideas into reality. Read more
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval. Read more
Evidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening. Read more
Association aims to bring attention to the often-overlooked links between air pollution and lung cancer. Read more
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more